Back to Journals » Lung Cancer: Targets and Therapy » Volume 8
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
11,758 | Dovepress* | 8,386+ | 1,336 | 9,722 | |
PubMed Central* | 3,372 | 482 | 3,854 | ||
Totals | 11,758 | 1,818 | 13,576 | ||
*Since 13 October 2017 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
6 | 1 | 0 | 0 | 0 | 5 |
View citations on PubMed and Google Scholar